Targeting metabolic pathways can regulate immune cell function by inhibiting key enzymes in glycolysis (such as GLUT1 and HK2) or modulating OXPHOS to reverse the Warburg effect; targeting mtROS can induce excessive mitochondrial ROS, damage mitochondrial DNA, trigger immunogenic cell death (ICD), and activate anti-tumor immunity. This evidence concerns the gene SLC2A1 and neoplasm.